March 9, 2026
TOPLINE: A few exhaled volatile organic compounds — specifically decane and nonadecane — showed potential to identify allergic patients among those with chronic rhinitis, with 76.5% […]
March 5, 2026
PHILADELPHIA — The investigational drug navenibart reduced attacks of hereditary angioedema by an average 91% over 1 year with only twice-yearly dosing and no serious adverse […]
March 5, 2026
Chronic rhinosinusitis may be linked to an increased risk for cancer, according to a study of patients in Asia. The study found that chronic rhinosinusitis was […]
March 4, 2026
TOPLINE: A 5-day amoxicillin challenge was feasible for evaluating delayed penicillin allergy, with more than 80% of participants completing the protocol; immune‑mediated reactions were uncommon but […]
March 3, 2026
Food allergy affects more than 33 million people in the United States — about 1 in 10 adults and 1 in 13 children — and the […]
March 2, 2026
PHILADELPHIA — The younger siblings of children who ate peanuts were more likely to develop peanut allergy, but that probability dropped substantially if the younger sibling […]
March 2, 2026
Adults with severe asthma were more likely to discontinue biologic therapy based on nonclinical reasons than based on side effects or perceived ineffectiveness, according to data […]
February 27, 2026
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has approved Xolremdi (mavorixafor, X4 Pharmaceuticals GmbH) for the treatment of WHIM syndrome, […]
February 26, 2026
TOPLINE: A volume‑based peanut oral immunotherapy (OIT) protocol using store‑bought peanut powder enabled 94% of children with peanut allergy to tolerate high-dose maintenance therapy and supported […]